Evidence for plasma-based circulating tumor DNA (ctDNA) as a prognostic and predictive marker in urothelial carcinoma is helping to transform the diagnostic and management landscape. Joaquin ...

Consistent with previous studies, ctDNA status predicted 3-year DFS, which was 86.5% in patients with ctDNA-negative tests and 33.7% among patients with positive results (P <0.0001).

During her presentation, Shah commented on the study’s findings regarding the role of ctDNA testing in guiding adjuvant treatment decisions. “When asked whether postoperative ctDNA results ...

Recurrence included ctDNA recurrence, radiographic recurrence, or concurrent ctDNA and imaging recurrence. Over a median duration of 26 months, 45 patients (24.5%) had ctDNA- or imaging-confirmed ...

In the combination group, median recurrence-free survival (RFS) was 16.59 months in patients who had ctDNA positivity at baseline versus 68.11 months in those who were ctDNA negative (HR 2.98, 95% ...

At ctDNA levels below 10 mutant copies/mL (0.25% VAF) it can reassure patients that progression is unlikely, while levels above 100 copies/mL (2.5% VAF) are associated with at least a 90% chance ...

Patients with hormone receptor (HR)-positive early breast cancer who underwent ultra-sensitive tissue-free circulating tumor DNA (ctDNA) demonstrated detections of ctDNA, according to findings from a ...

Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.

Hello! Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more.

Of the 1,901 patients who underwent ctDNA testing to determine their eligibility for the trial, 147 (7.7%) had detectable ctDNA and were therefore eligible.

Source: Dickinson K, et al. JAMA Netw Open. 2024;doi: 10.1001/jamanetworkopen.2024.31722.